$GNMX News
Last published 6y ago
- 6y agoGNMXGHFDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic TestFDA Press ReleasesToday, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies — NGS and liqu ...
- 6y agoCERCGNMXCerecor and Aevi Genomic Medicine Complete MergerGlobeNewswire-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE, Md.,...
- 6y agoCELGTEVACNTXGNMX+1NexImmune Appoints Sol Barer as Chairman of the Board of DirectorsGlobeNewswireGAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation...
- 6y agoCERCGNMXCerecor to Acquire Aevi Genomic MedicineGlobeNewswire-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases-Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical...
- 6y agoGNMXCERCCerecor to Acquire Aevi Genomic MedicinePR NewswireAevi Genomic Medicine, Inc. ("Aevi") (Nasdaq: GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. ("Cerecor") ...
- 7y agoGNMXAevi Genomic Medicine, Inc. Receives Positive Nasdaq Listing DeterminationPR NewswireAevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company's...
- 7y agoGNMXAevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 AntibodyPR NewswireAevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced that it has obtained the right to exercise an exclusive global license for...
- 7y agoGNMXAevi Genomic Medicine to Present at the 2019 Wedbush PacGrow Healthcare ConferencePR NewswireAevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that Michael F. Cola, President and Chief Executive Officer, will present...
- 7y agoGNMXAevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 InhibitorPR NewswireAevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with OSI Pharmaceuticals, LLC,...
- 8y agoGNMXAevi Genomic Medicine's (GNMX) CEO Mike Cola on Q4 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
- 9y agoGNMXAevi Genomic Medicine's (GNMX) CEO Michael Cola on Q1 2017 Results - Earnings Call TranscriptEarnings Call Transcripts